KLP Kapitalforvaltning AS Boosts Stock Holdings in LeMaitre Vascular, Inc. $LMAT

KLP Kapitalforvaltning AS boosted its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 15.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,400 shares of the medical instruments supplier’s stock after acquiring an additional 600 shares during the period. KLP Kapitalforvaltning AS’s holdings in LeMaitre Vascular were worth $365,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. Avantax Advisory Services Inc. grew its stake in LeMaitre Vascular by 1.5% during the first quarter. Avantax Advisory Services Inc. now owns 15,035 shares of the medical instruments supplier’s stock valued at $1,261,000 after acquiring an additional 229 shares in the last quarter. HighTower Advisors LLC grew its stake in LeMaitre Vascular by 4.2% during the first quarter. HighTower Advisors LLC now owns 5,920 shares of the medical instruments supplier’s stock valued at $497,000 after acquiring an additional 237 shares in the last quarter. Harbor Capital Advisors Inc. grew its stake in LeMaitre Vascular by 1.1% during the second quarter. Harbor Capital Advisors Inc. now owns 22,282 shares of the medical instruments supplier’s stock valued at $1,851,000 after acquiring an additional 245 shares in the last quarter. US Bancorp DE grew its stake in LeMaitre Vascular by 36.0% during the first quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier’s stock valued at $117,000 after acquiring an additional 368 shares in the last quarter. Finally, Geneos Wealth Management Inc. grew its stake in LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after buying an additional 398 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Trading Down 0.3%

Shares of LMAT opened at $86.60 on Monday. The firm has a market cap of $1.96 billion, a price-to-earnings ratio of 42.04, a PEG ratio of 2.23 and a beta of 0.77. The company has a debt-to-equity ratio of 0.46, a quick ratio of 11.74 and a current ratio of 13.96. LeMaitre Vascular, Inc. has a fifty-two week low of $71.42 and a fifty-two week high of $109.58. The firm has a 50 day moving average price of $91.86 and a 200-day moving average price of $86.46.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.03. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The company had revenue of $63.15 million during the quarter, compared to analyst estimates of $62.48 million. During the same period in the prior year, the business posted $0.52 EPS. The firm’s revenue was up 15.0% compared to the same quarter last year. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. As a group, equities research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 4th. Shareholders of record on Thursday, August 21st were given a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend was Thursday, August 21st. LeMaitre Vascular’s payout ratio is presently 38.83%.

Analysts Set New Price Targets

A number of equities analysts have commented on LMAT shares. Weiss Ratings reissued a “buy (b-)” rating on shares of LeMaitre Vascular in a research note on Wednesday, October 8th. Barrington Research reissued an “outperform” rating and issued a $95.00 price target on shares of LeMaitre Vascular in a research note on Wednesday, October 15th. Finally, Cantor Fitzgerald boosted their price target on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Three investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $97.60.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, Director David B. Roberts sold 10,815 shares of the business’s stock in a transaction on Monday, August 11th. The shares were sold at an average price of $92.39, for a total transaction of $999,197.85. Following the transaction, the director directly owned 17,976 shares of the company’s stock, valued at approximately $1,660,802.64. The trade was a 37.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bridget A. Ross sold 2,500 shares of the company’s stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $94.00, for a total transaction of $235,000.00. Following the completion of the sale, the director directly owned 2,916 shares in the company, valued at $274,104. This represents a 46.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 120,815 shares of company stock valued at $11,280,206 in the last 90 days. 9.50% of the stock is owned by company insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.